Phase 3 Study of JP-1366: Efficacy and Safety of JP-1366 as Maintenance Therapy in Subjects With Healed Erosive Esophagitis

NCT07732075 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

384

Enrollment

INDUSTRY

Sponsor class

Conditions

Maintenance of Healed Erosive Gastroesophageal Reflux Disease (ERD)

Interventions

DRUG: JP-1366 10 mg
DRUG: Lansoprazole 15mg

Sponsor

Onconic Therapeutics Inc.